keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/29164346/impact-of-prior-androgen-receptor-axis-targeted-agents-on-the-clinical-activity-of-subsequent-docetaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-comparative-assessment-between-abiraterone-acetate-and-enzalutamide
#1
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama, Atsushi Otsuka
The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This study included a total of 114 mCRPC patients consisting of 54 and 60 who progressed following treatment with AA and Enz, respectively, prior to the introduction of docetaxel, and compared oncological outcomes with docetaxel between these two groups...
November 21, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29164326/men-with-family-history-of-prostate-cancer-have-a-higher-risk-of-disease-recurrence-after-radical-prostatectomy
#2
Mark Thalgott, Martina Kron, Johannes M Brath, Donna P Ankerst, Ian M Thompson, Juergen E Gschwend, Kathleen Herkommer
PURPOSE: We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP). METHODS: Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed...
November 21, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29156544/endogenous-sphingolipid-signaling-pathway-implicated-in-the-action-of-croton-membranaceus-on-the-prostate-gland-in-bph-patients
#3
George Awuku Asare, Yvonne Anang, Daniel K Afriyie, Brodrick Yeboah Amoah, Bernice Asiedu, Derek Doku, Hannah Serwah Ocansey, Nana Yaw Odei Danso, Prince Tekpor, Sarah Osam
Background: Croton membranaceus extract has apoptotic effects on BPH-1 cells. This study determined if the apoptotic effects were created through the ceramide pathway. Methods: The study was a follow-up to a previous observational study of 30 histologically confirmed patients with benign prostatic hyperplasia (BPH) who were on C. membranaceus ethanolic extract at 20 mg t.i.d orally for 3 mo. Thereafter, total and free prostate-specific antigen (PSA), lipid profile plus Apo lipoprotein A and B, ceramide/Sphingophospho-kinase 1 (SphK1) and 2 (SphK2), sphingosine lyase (SPL), the cytotoxic adducts of oxidative stress 4-hydroxy-2-nonenal (4HNE) and malondialdehyde (MDA), were determined...
November 18, 2017: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/29137895/a-four-kallikrein-panel-and-%C3%AE-microseminoprotein-in-predicting-high-grade-prostate-cancer-on-biopsy-an-independent-replication-from-the-finnish-section-of-the-european-randomized-study-of-screening-for-prostate-cancer
#4
Melissa Assel, Liisa Sjöblom, Teemu J Murtola, Kirsi Talala, Paula Kujala, Ulf-Håkan Stenman, Kimmo Taari, Anssi Auvinen, Andrew Vickers, Tapio Visakorpi, Teuvo L Tammela, Hans Lilja
BACKGROUND: A panel of four kallikrein markers (total, free, and intact prostate-specific antigen [PSA] and human kallikrein-related peptidase 2 [hK2]) improves predictive accuracy for Gleason score ≥7 (high-grade) prostate cancer among men biopsied for elevated PSA. A four-kallikrein panel model was originally developed and validated by the Dutch center of the European Randomized Study of Screening for Prostate Cancer (ERSPC). The kallikrein panel is now commercially available as 4Kscore™...
November 11, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29126389/safety-and-efficacy-of-abiraterone-acetate-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer-an-italian-multicenter-real-life-study
#5
Luca Cindolo, Clara Natoli, Cosimo De Nunzio, Michele De Tursi, Maurizio Valeriani, Silvana Giacinti, Salvatore Micali, Mino Rizzo, Giampaolo Bianchi, Eugenio Martorana, Marcello Scarcia, Giuseppe Mario Ludovico, Pierluigi Bove, Anastasia Laudisi, Oscar Selvaggio, Giuseppe Carrieri, Maida Bada, Pietro Castellan, Stefano Boccasile, Pasquale Ditonno, Paolo Chiodini, Paolo Verze, Vincenzo Mirone, Luigi Schips
BACKGROUND: To evaluate the safety and efficacy of abiraterone acetate (AA) in the "real life" clinical practice for men with chemotherapy-naïve metastatic castration-resistant prostate. METHODS: A consecutive series of patients with mCRPC in 9 Italian tertiary centres treated with AA was collected. Demographics, clinical parameters, treatment outcomes and toxicity were recorded. The Brief Pain Inventory scale Q3 was tracked and patient treatment satisfaction was evaluated...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29094386/characteristics-and-outcome-of-prostate-cancer-patients-with-overall-biopsy-gleason-score-3-4-7-and-highest-gleason-score-3-4-7-or-3-4-7
#6
Esther I Verhoef, Charlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, Chris H Bangma, Luca Incrocci, Theodorus H van der Kwast, Monique J Roobol, Geert J van Leenders
AIM: Prostate cancer heterogeneity and multifocality might result in different Gleason scores (GS) at individual biopsy cores. According to WHO/ISUP guidelines, the GS in each biopsy core should be recorded with optional reporting of overall GS for the entire case. We aimed to compare the clinicopathologic characteristics and outcome of men with overall biopsy GS 3+4=7 with highest GS 3+4=7 (HI=OV) to those with highest GS > 3+4=7 (HI>OV). METHODS AND RESULTS: Prostate cancer biopsies from the European Randomized Study of Screening for Prostate Cancer (ERSPC) were revised according to WHO/ISUP 2014 guidelines (n=1031)...
November 1, 2017: Histopathology
https://www.readbyqxmd.com/read/29046789/a-retrospective-study-of-late-adverse-events-in-proton-beam-therapy-for-prostate-cancer
#7
Hirokazu Makishima, Hitoshi Ishikawa, Keiichi Tanaka, Yutaro Mori, Masashi Mizumoto, Kayoko Ohnishi, Teruhito Aihara, Nobuyoshi Fukumitsu, Toshiyuki Okumura, Hideyuki Sakurai
The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis included 93 patients with a median age of 68 years (range, 49-81 years). A total of 7, 32 and 54 prostate cancer patients were classified as low-, intermediate- and high-risk, respectively, as follows: High-risk, T≥3a or prostate-specific antigen (PSA) ≥20 ng/ml or Gleason Score ≥8; low-risk, T ≤2b and PSA≤10 ng/ml and Gleason Score=6; intermediate-risk, all other combinations...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29046289/a-novel-model-to-predict-positive-prostate-biopsy-based-on-serum-androgen-level
#8
Takeshi Ujike, Motohide Uemura, Atsunari Kawashima, Akira Nagahara, Kazutoshi Fujita, Yasushi Miyagawa, Norio Nonomura
Circulating levels of prostate-specific antigen (PSA) and testosterone are widely used for detection of prostate cancer prior to prostate biopsy; however both remain controversial. Effective screening strategies based on quantitative factors could help avoid unnecessary biopsies. Here, we sought to clarify the predictive value of free testosterone (FT) versus total testosterone (TT) in identifying patients likely to have positive biopsies. This study aims to develop a novel model for predicting positive prostate biopsy based on serum androgen levels...
October 18, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29042308/abiraterone-followed-by-enzalutamide-versus-enzalutamide-followed-by-abiraterone-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer
#9
Nobuaki Matsubara, Yoko Yamada, Ken-Ichi Tabata, Takefumi Satoh, Naoto Kamiya, Hiroyoshi Suzuki, Takashi Kawahara, Hiroji Uemura, Akihiro Yano, Satoru Kawakami, Masafumi Otsuka, Satoshi Fukasawa
BACKGROUND: Abiraterone (AA) and enzalutamide (ENZA) are increasingly being used in chemotherapy-naive patients with metastatic castration-resistant prostate cancer owing to efficacy and favorable toxicity. However, the order in which they should be administered has not been determined. PATIENTS AND METHODS: We retrospectively reviewed the records of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who had received sequential treatment with either AA followed by ENZA (AA-ENZA) or the converse (ENZA-AA)...
September 23, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29034236/prognostic-value-of-the-new-prostate-cancer-international-society-of-urological-pathology-grade-groups
#10
Anne Offermann, Silke Hohensteiner, Christiane Kuempers, Julika Ribbat-Idel, Felix Schneider, Finn Becker, Marie Christine Hupe, Stefan Duensing, Axel S Merseburger, Jutta Kirfel, Markus Reischl, Verena Lubczyk, Rainer Kuefer, Sven Perner
Gleason grading is the best independent predictor for prostate cancer (PCa) progression. Recently, a new PCa grading system has been introduced by the International Society of Urological Pathology (ISUP) and is recommended by the World Health Organization (WHO). Following studies observed more accurate and simplified grade stratification of the new system. Aim of this study was to compare the prognostic value of the new grade groups compared to the former Gleason Grading and to determine whether re-definition of Gleason Pattern 4 might reduce upgrading from prostate biopsy to radical prostatectomy (RP) specimen...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/29031682/-rates-of-total-and-free-psa-prescriptions-in-france-2012-2014
#11
Philippe Tuppin, Claire Leboucher, Gabrielle Peyre-Lanquar, Pierre-Jean Lamy, Pierre Gabach, Xavier Rébillard
BACKGROUND: In 2010, the French Haute Autorité de santé (National Health Authority) confirmed the limited value of prostate cancer (PCa) screening by total prostate-specific antigen (PSA) assay. OBJECTIVE: This study was designed to determine the modalities of ordering total PSA or free PSA assays (in the absence of PCa) according to various parameters and the corresponding sums reimbursed. METHODS: Men aged 40 years and older covered by the national health insurance general scheme (73% of the French population) between 2012 and 2014 were selected...
October 11, 2017: La Presse Médicale
https://www.readbyqxmd.com/read/29022058/-psma-radioguided-surgery-in-localised-recurrent-prostate-cancer
#12
REVIEW
T Horn, I Rauscher, M Eiber, J E Gschwend, T Maurer
Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for PSMA-RGS is a positive (68)Ga-PSMA positron emission tomography (PET) scan with a preferably singular soft tissue or lymph node recurrence. The first 63 patients treated with PSMA-RGS were analyzed. The extracorporal analysis of a total of 277 tissue specimens yielded the following test quality criteria regarding the presence of malignant tissue: sensitivity 86...
November 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28981526/association-between-polymorphisms-in-sex-hormones-synthesis-and-metabolism-and-prostate-cancer-aggressiveness
#13
Inmaculada Robles-Fernandez, Luis Javier Martinez-Gonzalez, Manrique Pascual-Geler, Jose Manuel Cozar, Ignacio Puche-Sanz, Maria Jose Serrano, Jose Antonio Lorente, Maria Jesus Alvarez-Cubero
Novel biomarkers for prostate cancer (PCa) diagnosis and prognosis are necessary to improve the accuracy of current ones employed in clinic. We performed a retrospective study between the association of several polymorphisms in the main genes involved in the synthesis and metabolism of sex hormones and PCa risk and aggressiveness. A total of 311 Caucasian men (155 controls and 156 patients) were genotyped for 9 SNPs in AR, CYP17A1, LHCGR, ESR1 and ESR2 genes. Diagnostic PSA serum levels, Gleason score, tumor stage, D´Amico risk and data of clinical progression were obtained for patients at the moment of the diagnosis and after 54 months of follow-up...
2017: PloS One
https://www.readbyqxmd.com/read/28975586/impact-of-treatment-delay-in-radium-223-therapy-of-metastatic-castration-resistant-prostate-cancer-patients
#14
Marie Øbro Fosbøl, Peter Meidahl Petersen, Gedske Daugaard, Søren Holm, Andreas Kjaer, Jann Mortensen
BACKGROUND: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shortage of Ra-223 occurred for 2 months due to production irregularities. The aim of this study was to assess whether prolonged interval between Ra-223 cycles to non-disease related causes had a negative impact on clinical outcome of therapy. MATERIALS AND METHODS: Retrospective single-center study of mCRPC patients who initiated Ra-223 therapy in the period from March 2014 to February 2015...
October 3, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28958194/active-surveillance-for-localized-prostate-cancer-update-of-a-prospective-single-center-cohort
#15
Mathias Thostrup, Frederik B Thomsen, Peter Iversen, Klaus Brasso
OBJECTIVE: The purpose of active surveillance (AS) is to reduce overtreatment of men with localized prostate cancer (PCa) without compromising survival. The objective of this study was to update a large Scandinavian single-center AS cohort. Furthermore, the use of curative treatment and subsequent risk of biochemical recurrence were investigated and compared in men with very low-risk, low-risk and intermediate-risk PCa in the cohort. MATERIALS AND METHODS: In total, 451 men were followed on AS and monitored with prostate-specific antigen (PSA) tests, digital rectal examinations and rebiopsies...
September 28, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28939384/are-prostate-biopsies-necessary-for-all-patients-75years-and-older
#16
Yuke Chen, Yu Fan, Yang Yang, Jie Jin, Liqun Zhou, Zhisong He, Zheng Zhao, Qun He, Xiaoying Wang, Wei Yu, Shiliang Wu
PURPOSE: To develop nomograms predicting prostate cancer (PCa) and high-grade PCa (HGPCa) in the elderly population. METHODS: We reviewed the data of patients aged 75years and older who underwent first-time prostate biopsy and multiparametric magnetic resonance imaging (mpMRI). The nomograms were developed based on multivariate analysis and evaluated. We performed the external validation and calibration of the risk calculators from the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate Cancer Prevention Trial (PCPT)...
September 19, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28939004/the-phase-3-cou-aa-302-study-of-abiraterone-acetate-plus-prednisone-in-men-with-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-stratified-analysis-based-on-pain-prostate-specific-antigen-and-gleason-score
#17
Kurt Miller, Joan Carles, Jürgen E Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D Brookman-May
BACKGROUND: In the COU-AA-302 study (NCT00887198), abiraterone acetate plus prednisone (AAP) significantly improved outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) versus prednisone alone. Baseline clinical parameters predicting that treatment response could help inform clinical decisions were explored. OBJECTIVE: To identify patients who derive the greatest clinical benefit from AAP treatment. DESIGN, SETTING, AND PARTICIPANTS: A total of 1088 mCRPC patients treated with either AAP or prednisone in the first-line setting in COU-AA-302 were included in this post hoc analysis...
September 20, 2017: European Urology
https://www.readbyqxmd.com/read/28919294/studying-the-efficacy-of-escalated-dose-conformal-radiation-therapy-in-prostate-carcinoma-pakistan-experience
#18
Asad Zamir, Ahmad Farooq, Hasan Nisar, Ismat Fatima, Irfan Ullah Khan, Misbah Masood, Abubaker Shahid
BACKGROUND: Our objective in this study was to evaluate the role and benefits in terms of local toxicity and biochemical disease-free survival (bDFS) following escalated-dose conformal radiation therapy in prostate adenocarcinoma. METHODS: The study population was composed of 53 patients with histologically proven T1b-T4, NO, MO prostate adenocarcinoma, having any Gleason score with prostate-specific antigen (PSA) of less than 50 ng/mL at diagnosis, given escalated dose EBRT (74 Gy) during the period between January 2011 and December 2013, retrospectively and evaluated for a period of 2 years post-radiation...
September 14, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28910345/circulating-mrnas-and-mirnas-as-candidate-markers-for-the-diagnosis-and-prognosis-of-prostate-cancer
#19
MULTICENTER STUDY
Marilesia Ferreira de Souza, Hellen Kuasne, Mateus de Camargo Barros-Filho, Heloísa Lizotti Cilião, Fabio Albuquerque Marchi, Paulo Emilio Fuganti, Alexandre Rossi Paschoal, Silvia Regina Rogatto, Ilce Mara de Syllos Cólus
Circulating nucleic acids are found in free form in body fluids and may serve as minimally invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the potential application of circulating mRNAs and microRNAs (miRNAs) in prostate cancer (PCa). The Cancer Genome Atlas (TCGA) database was used for an in silico analysis to identify circulating mRNA and miRNA as potential markers of PCa. A total of 2,267 genes and 49 miRNAs were differentially expressed between normal and tumor samples...
2017: PloS One
https://www.readbyqxmd.com/read/28903426/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#20
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
August 15, 2017: Oncotarget
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"